Interventions and outcomes of adult patients with B-ALL progressing after CD19 chimeric antigen receptor T-cell therapy

嵌合抗原受体 Blinatumoab公司 医学 内科学 CD19 挽救疗法 肿瘤科 免疫疗法 免疫学 细胞疗法 抗原 化疗 干细胞 癌症 生物 遗传学
作者
Kitsada Wudhikarn,Jessica Flynn,Isabelle Rivière,Mithat Gönen,Xiuyan Wang,Brigitte Sénéchal,Kevin J. Curran,Mikhail Roshal,P. Maslak,Mark B. Geyer,Elizabeth Halton,Claudia Diamonte,Marco L. Davila,Michel Sadelain,Renier J. Brentjens,Jae H. Park
出处
期刊:Blood [American Society of Hematology]
卷期号:138 (7): 531-543 被引量:37
标识
DOI:10.1182/blood.2020009515
摘要

Abstract CD19-targeted chimeric antigen receptor (CAR) T-cell therapy has become a breakthrough treatment of patients with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL). However, despite the high initial response rate, the majority of adult patients with B-ALL progress after CD19 CAR T-cell therapy. Data on the natural history, management, and outcome of adult B-ALL progressing after CD19 CAR T cells have not been described in detail. Herein, we report comprehensive data of 38 adult patients with B-ALL who progressed after CD19 CAR T therapy at our institution. The median time to progression after CAR T-cell therapy was 5.5 months. Median survival after post–CAR T progression was 7.5 months. A high disease burden at the time of CAR T-cell infusion was significantly associated with risk of post–CAR T progression. Thirty patients (79%) received salvage treatment of post–CAR T disease progression, and 13 patients (43%) achieved complete remission (CR), but remission duration was short. Notably, 7 (58.3%) of 12 patients achieved CR after blinatumomab and/or inotuzumab administered following post–CAR T failure. Multivariate analysis revealed that a longer remission duration from CAR T cells was associated with superior survival after progression following CAR T-cell therapy. In summary, overall prognosis of adult B-ALL patients progressing after CD19 CAR T cells was poor, although a subset of patients achieved sustained remissions to salvage treatments, including blinatumomab, inotuzumab, and reinfusion of CAR T cells. Novel therapeutic strategies are needed to reduce risk of progression after CAR T-cell therapy and improve outcomes of these patients.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
诚心的若南完成签到,获得积分10
1秒前
YJH完成签到,获得积分10
1秒前
心靖完成签到,获得积分10
1秒前
2秒前
qing_he完成签到 ,获得积分10
2秒前
3秒前
芋圆完成签到,获得积分10
4秒前
sfzz完成签到,获得积分10
5秒前
Henry应助Cindy采纳,获得200
6秒前
rarfen发布了新的文献求助10
8秒前
脑洞疼应助ashore采纳,获得10
8秒前
面包完成签到,获得积分10
9秒前
10秒前
Henry应助Cindy采纳,获得200
11秒前
12秒前
默默荔枝完成签到 ,获得积分10
12秒前
12秒前
天天快乐应助obsession采纳,获得10
13秒前
14秒前
陈曦发布了新的文献求助10
14秒前
金烛关注了科研通微信公众号
15秒前
15秒前
15秒前
16秒前
rarfen完成签到,获得积分10
16秒前
FashionBoy应助德德采纳,获得10
18秒前
Hh发布了新的文献求助10
18秒前
moncypool发布了新的文献求助30
19秒前
Hello应助橘子采纳,获得10
19秒前
20秒前
loomsis完成签到,获得积分10
21秒前
shin2333完成签到,获得积分10
22秒前
jjjjjjjj完成签到,获得积分0
22秒前
寒冷静枫发布了新的文献求助10
22秒前
iNk应助高大的战斗机采纳,获得10
24秒前
25秒前
按照习完成签到 ,获得积分10
26秒前
26秒前
云宇完成签到,获得积分10
27秒前
勤劳向真发布了新的文献求助10
27秒前
高分求助中
Evolution 10000
ISSN 2159-8274 EISSN 2159-8290 1000
Becoming: An Introduction to Jung's Concept of Individuation 600
Ore genesis in the Zambian Copperbelt with particular reference to the northern sector of the Chambishi basin 500
A new species of Coccus (Homoptera: Coccoidea) from Malawi 500
A new species of Velataspis (Hemiptera Coccoidea Diaspididae) from tea in Assam 500
PraxisRatgeber: Mantiden: Faszinierende Lauerjäger 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3162844
求助须知:如何正确求助?哪些是违规求助? 2813816
关于积分的说明 7902135
捐赠科研通 2473442
什么是DOI,文献DOI怎么找? 1316849
科研通“疑难数据库(出版商)”最低求助积分说明 631545
版权声明 602187